PMC:7784830 / 24106-24348 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"402","span":{"begin":0,"end":32},"obj":"Disease"},{"id":"403","span":{"begin":34,"end":38},"obj":"Disease"}],"attributes":[{"id":"A402","pred":"tao:has_database_id","subj":"402","obj":"MESH:D018352"},{"id":"A403","pred":"tao:has_database_id","subj":"403","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Middle East Respiratory Syndrome (MERS) vaccine was developed using recombinant nanoparticle based vaccine technology. The vaccine showed positive results in inhibiting the virus when administered along with its patented adjuvant formulations"}